Results 211 to 220 of about 35,533 (292)
Fisetin-mediated PPAR-γ upregulation: a novel therapeutic approach for corpus cavernosum smooth-muscle-cell apoptosis and restoration of erectile function after cavernous nerve injury. [PDF]
Fu Y, Zhang X, Xu R, Lv B.
europepmc +1 more source
Objective To present large‐scale safety outcomes, with a particular focus on postoperative bleeding following Aquablation for benign prostatic hyperplasia. Patients and Methods Patients who underwent Aquablation between 2019 and 2024 across Asia, Europe, and North America were assessed to evaluate trends in treated prostate sizes, which were visualised
Mario Bitar +7 more
wiley +1 more source
Erectile function after laparoscopic versus robotic-assisted radical prostatectomy: A systematic review and meta-analysis. [PDF]
Pina AJ +6 more
europepmc +1 more source
The cost‐effectiveness of intraoperative margin assessment strategies during radical prostatectomy
Objective To determine whether current intraoperative margin assessment (IOMA) techniques (such as Neurovascular Structure Adjacent Frozen‐section Examination [NeuroSAFE] or confocal laser microscopy [CLM]) used during radical prostatectomy (RP) to enhance nerve‐sparing surgery (NSS) while reducing positive surgical margins (PSMs) justify their extra ...
Joost van Drumpt +7 more
wiley +1 more source
Icariin inhibits hyperglycemia-induced cell death in penile cavernous tissue and improves erectile function in type 1 diabetic rats. [PDF]
Yang H, Xiong W, Jiang J, Jiang R.
europepmc +1 more source
Cave Palaeolithic of the Ural Mountains – a review
The Ural Mountains are of fundamental importance for studying early human migrations along the geographical limits between Europe and Asia. Geological processes and past climates gave rise to numerous caves, mostly in Palaeozoic carbonate formations.
Jiri Chlachula
wiley +1 more source
Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen +3 more
wiley +1 more source

